Structural and Functional Characterization of a Cross-Reactive Dengue Virus Neutralizing Antibody that Recognizes a Cryptic Epitope

被引:41
|
作者
Li, Jie [1 ,2 ,3 ,4 ,5 ]
Watterson, Daniel [2 ,3 ,4 ]
Chang, Chiung-Wen [2 ]
Che, Xiao-Yan [1 ]
Li, Xiao-Quan [1 ]
Ericsson, Daniel J. [2 ,4 ]
Qiu, Li-Wen [1 ]
Cai, Jian-Piao [1 ]
Chen, Jing [1 ]
Fry, Scott R. [3 ,6 ]
Cheung, Stacey T. M. [2 ]
Cooper, Matthew A. [2 ,3 ,4 ]
Young, Paul R. [2 ,4 ]
Kobe, Bostjan [2 ,4 ]
机构
[1] Southern Med Univ, ZhuJiang Hosp, Div Lab Med, Guangzhou 510282, Guangdong, Peoples R China
[2] Univ Queensland, Sch Chem & Mol Biosci, Brisbane, Qld 4072, Australia
[3] Univ Queensland, Inst Mol Biosci, Div Chem & Struct Biol, Brisbane, Qld 4072, Australia
[4] Univ Queensland, Australian Infect Dis Res Ctr, Brisbane, Qld 4072, Australia
[5] Anhui Med Univ, Affiliated Hosp 1, Dept Clin Lab, Hefei 230022, Anhui, Peoples R China
[6] Ellume Pty Ltd, 57 Didsbury St, East Brisbane, Qld 4169, Australia
基金
澳大利亚研究理事会; 英国医学研究理事会; 中国国家自然科学基金; 澳大利亚国家健康与医学研究理事会;
关键词
ENVELOPE PROTEIN; DOMAIN III; VACCINE; RECOMBINANT; FUSION; MECHANISM; BINDING; GLYCOPROTEIN; FLAVIVIRUSES; MATURATION;
D O I
10.1016/j.str.2017.11.017
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Understanding the molecular basis of the neutralizing antibody response to dengue virus (DENV) is an essential component in the design and development of effective vaccines and immunotherapeutics. Here we present the structure of a cross-reactive, neutralizing antibody, 3E31, in complex with domain III (DIII) of the DENV envelope (E) protein and reveal a conserved, temperature-sensitive, cryptic epitope on DIII that is not available in any of the known conformations of E on the dengue virion. We observed that 3E31 inhibits E-mediated membrane fusion, suggesting that the antibody is able to neutralize virus through binding an as-yet uncharacterized intermediate conformation of DENV E and sterically block trimer formation. Finally, we show that, unlike cross-reactive fusion peptide-specific antibodies, 3E31 does not promote antibody-dependent enhancement of infection at sub-neutralizing concentrations. Our results highlight the 3E31 epitope on the E protein DIII as a promising target for immunotherapeutics or vaccine design.
引用
收藏
页码:51 / +
页数:13
相关论文
共 50 条
  • [1] A Human PrM Antibody That Recognizes a Novel Cryptic Epitope on Dengue E Glycoprotein
    Chan, Annie Hoi Yi
    Tan, Hwee Cheng
    Chow, Angelia Yee
    Lim, Angeline Pei Chiew
    Lok, Shee Mei
    Moreland, Nicole J.
    Vasudevan, Subhash G.
    MacAry, Paul A.
    Ooi, Eng Eong
    Hanson, Brendon J.
    PLOS ONE, 2012, 7 (04):
  • [2] Dengue virus cross-reactive hemagglutination inhibition antibody responses in patients with primary dengue virus infection
    Anantapreecha, Surapee
    A-nuegoonpipat, Atchareeya
    Prakrong, Songthum
    Chanama, Sumalee
    Sa-ngasang, Areerat
    Sawanpanyalert, Pathom
    Kurane, Ichiro
    JAPANESE JOURNAL OF INFECTIOUS DISEASES, 2007, 60 (05) : 267 - 270
  • [3] Charged Residue Implantation Improves the Affinity of a Cross-Reactive Dengue Virus Antibody
    Wei, Huiling
    Tan, Jie
    Zhou, Bingjie
    Guan, Xiaotong
    Zhong, Qiaoxian
    Wang, Jiaqi
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (08)
  • [4] Serotype-specific and cross-reactive neutralizing antibody responses in cynomolgus monkeys after infection with multiple dengue virus serotypes
    Ito, Mikako
    Katakai, Yuko
    Ono, Fumiko
    Akari, Hirofumi
    Mukai, Ryo-zabro
    Takasaki, Tomohiko
    Kotaki, Akira
    Kurane, Ichiro
    ARCHIVES OF VIROLOGY, 2011, 156 (06) : 1073 - 1077
  • [5] Serotype-specific and cross-reactive neutralizing antibody responses in cynomolgus monkeys after infection with multiple dengue virus serotypes
    Mikako Ito
    Yuko Katakai
    Fumiko Ono
    Hirofumi Akari
    Ryo-zabro Mukai
    Tomohiko Takasaki
    Akira Kotaki
    Ichiro Kurane
    Archives of Virology, 2011, 156 : 1073 - 1077
  • [6] COVID-19 serum can be cross-reactive and neutralizing against the dengue virus, as observed by the dengue virus neutralization test
    Nath, Himadri
    Mallick, Abinash
    Roy, Subrata
    Kayal, Tathagata
    Ranjan, Sumit
    Sengupta, Susanta
    Sukla, Soumi
    Biswas, Subhajit
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2022, 122 : 576 - 584
  • [7] Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus
    Priyamvada, Lalita
    Quicke, Kendra M.
    Hudson, William H.
    Onlamoon, Nattawat
    Sewatanon, Jaturong
    Edupuganti, Srilatha
    Pattanapanyasat, Kovit
    Chokephaibulkit, Kulkanya
    Mulligan, Mark J.
    Wilson, Patrick C.
    Ahmed, Rafi
    Suthar, Mehul S.
    Wrammert, Jens
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2016, 113 (28) : 7852 - 7857
  • [8] Japanese Encephalitis DNA Vaccines with Epitope Modification Reduce the Induction of Cross-Reactive Antibodies against Dengue Virus and Antibody-Dependent Enhancement of Dengue Virus Infection
    Kotaki, Tomohiro
    Nagai, Yurie
    Yamanaka, Atsushi
    Konishi, Eiji
    Kameoka, Masanori
    VACCINES, 2022, 10 (09)
  • [9] Structural Basis for Marburg Virus Neutralization by a Cross-Reactive Human Antibody
    Hashiguchi, Takao
    Fusco, Marnie L.
    Bornholdt, Zachary A.
    Lee, Jeffrey E.
    Flyak, Andrew I.
    Matsuoka, Rei
    Kohda, Daisuke
    Yanagi, Yusuke
    Hammel, Michal
    Crowe, James E., Jr.
    Saphire, Erica Ollmann
    CELL, 2015, 160 (05) : 904 - 912
  • [10] Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody
    Zhang, MY
    Xiao, XD
    Sidorov, IA
    Choudhry, V
    Cham, F
    Zhang, PF
    Bouma, P
    Zwick, M
    Choudhary, A
    Montefiori, DC
    Broder, CC
    Burton, DR
    Quinnan, GV
    Dimitrov, DS
    JOURNAL OF VIROLOGY, 2004, 78 (17) : 9233 - 9242